The system, an intra-operative tissue assessment tool for early-stage breast cancer surgery, is intended to enable real-time detection of cancer at or near the surface of excised tissue specimens during breast cancer surgery. MarginProbe uses electromagnetic “signatures” to identify healthy and cancerous tissue during lumpectomy.
“The MarginProbe system was developed to address one of the longest standing unmet medical needs in the breast cancer surgical community,” said Daniel Levangie, CEO of Dune Medical Devices, in the release. “We have received resounding support from clinicians, advocacy organizations and patients alike, who have recognized the value of MarginProbe and intra-operative, real-time detection of cancer on the margin to potentially improve patient outcomes.”
Dune Medical Devices has offices in the United States, Israel and Switzerland.
Related Articles on FDA Clearances:
Medical Modeling Receives FDA Clearance for Virtual Surgical Planning System
EndoChoice Receives FDA Clearance for Water Bottle Cap Irrigation System
Avinger Receives FDA Clearance for Smaller, Longer Optical Coherence Tomography Catheter
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
